Neuphoria Therapeutics Achieves Target Enrollment in Phase 3 AFFIRM-1 Trial for BNC-210 in Social Anxiety Disorder.

Neuphoria Therapeutics has completed target enrollment of 332 participants in the AFFIRM-1 Phase 3 trial evaluating BNC-210 for social anxiety disorder (SAD). BNC-210 is a fast-acting, "as needed" treatment for SAD and has demonstrated rapid-onset, broad and meaningful anti-anxiety effects in completed clinical trials. The trial is expected to yield Phase 3 data early in the fourth quarter.